WHAT IS THE PURPOSE OF THE STUDY?

The purpose of this DiaPrevent research study is to see if the investigational Diamyd vaccine shots may help to preserve insulin producing capacity. In this phase III study, two out of three participants receive active vaccine and one out of three receives placebo (shots that look the same but without the active drug).

 

ABOUT TYPE 1 DIABETES

In type 1 diabetes, the cells that make insulin are under attack by the body´s own immune system. Studies have shown that people with diabetes who continue to produce their own insulin have less trouble with low blood sugar and fewer complications from their diabetes than people who no longer make any insulin.

 

Study participants need to:
  • be between 10 and 20 years old
  • be diagnosed with type 1 diabetes
    within the past 3 months
  • pass screening tests
Study participants will:
  • visit the clinic about 8 times during the next
    2 ½ years
  • receive shots
  • have their diabetes closely monitored with the help of their regular doctors or diabetes care teams
  • perform certain tests

WHAT IS DIAMYD VACCINE?

The Diamyd vaccine is an investigational drug aimed at saving a person's ability to make their own insulin for as long as possible. The vaccine is injected under the skin. Its active substance is a protein called glutamic acid decarboxylase (GAD).
The DiaPrevent diabetes research study is closed.